The subject matter of the instant invention relates to methods of compounding compositions comprising bacteriophage effective for treating bacterial infections, including but not limited to, multidrug resistant bacterial infections. The invention also relates to compositions, bacterial diversity sets, and phage libraries prepared according to the methods of the instant invention.

A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).

Provided herein are methods and compositions for killing a target bacterium. Also disclosed are engineered bacteriophages.

Disclosed herein are compositions that comprise one or more types of bacteriophage and methods of using such bacteriophages as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacterial populations and releasing nutrients into the environment for good bacteria in the digestive system of an individual.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains, and products and cocktails thereof, including F99/10, F110/10, F27/12, Psa_F83/13, Psa_F95/13, F391/08, Kle_F92/15, Kle_F105/15, Kle_F134/15, Kle_F141/15, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

The present invention describes a genetically modified Staphylococcus aureus bacteriophage VDX-10 comprising the DNA of the bacteriophage VDX-10 being altered by inserting a gene sequence that increases the ability of the bacteriophage to replicate faster as compared to unmodified VDX-10 bacteriophage; a method of producing the genetically modified Staphylococcus aureus bacteriophage VDX-10; and a method of treating infection in a patient by administering an amount of the genetically modified Staphylococcus aureus bacteriophage effective to eliminating the Staphylococcus bacteria cells, where the infection can be Ventilator-Associated Pneumonia (VAP) or bacteremia as incited by methicillin-resistant Staphylococcal aureus (MRSA) or methicillin-sensitive Staphylococcal aureus (MSSA).

Modified bacteriophage, uses thereof, and compositions containing the modified bacteriophage are described. The compositions are useful for human treatment and may treat various conditions, including bacterial infections.

A method for modifying the genome of a target phage is described. Compositions comprising such modified phage are also described. The compositions may be formulated as a medicament, which are useful for human treatment and may treat various conditions, including bacterial infections.

Bacteriophages are provided that infect strains of Enterococcus faecalis, an opportunistic bacterial pathogen that causes human disease. Also provided are methods of treating Enterococcus faecalis by therapeutic administration of such bacteriophages.